Market Research Logo

Global Cancer Immunotherapies Market 2016-2020

About Cancer Immunotherapies

Cancer immunotherapy works by enhancing the innate powers of the immune system. This has better chances of successfully fighting cancer for a long period. Also, immunotherapies have fewer side effects and can treat different types of cancer. Cancer immunotherapies make up nearly 50% of the cancer drugs market.

Technavio’s analysts forecast the global cancer immunotherapies market to grow at a CAGR of 15.17% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global cancer immunotherapies market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of cancer immunotherapies used to treat cancer.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Cancer Immunotherapies Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Amgen
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Takeda Pharmaceuticals
Other prominent vendors
  • AbbVie
  • ADC Therapeutics
  • Agensys
  • Astellas
  • AstraZeneca
  • Bayer
  • Biogen
  • Biotech Pharmaceutical
  • Boehringer-Ingelheim
  • Celgene
  • Celldex Therapeutics
  • Chugai Pharmaceutical
  • CTI Biopharma
  • Daiichi Sankyo
  • Eli Lilly
  • Fortress Biotech
  • Genmab
  • Immunomedics
  • Intas Pharmaceuticals
  • Janssen Biotech
  • Kyowa Hakko Kirin
  • MedImmune
  • Morphotek
  • Neovii Biotech
  • Novartis
  • OncoMed Pharmaceuticals
  • Pfizer
  • Sanofi
  • Seattle Genetics
  • Spectrum Pharmaceuticals
  • TG Therapeutics
  • XBiotech
Market driver
  • Increase in demand for cancer monoclonal antibodies
  • For a full, detailed list, view our report
Market challenge
  • Patent expiry of top-selling drugs
  • For a full, detailed list, view our report
Market trend
  • Emergence of targeted and combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Cancer Immunotherapies Market 2016-2020

Technavio recognizes the following companies as the key players in the global cancer immunotherapies market: Amgen Inc., Bristol-Myers Squibb, F. Hoffman-La Roche, GlaxoSmithKline Plc, Merck Inc., and Takeda Pharmaceuticals.

Other Prominent Vendors in the market are: AbbVie, ADC Therapeutics, Agensys, Astellas, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, Boehringer-Ingelheim, Celgene, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed, Pfizer, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, TG Therapeutics, and XBiotech.

Commenting on the report, an analyst from Technavio’s team said: “The emergence of targeted and combination therapies are being developed to treat all types of cancer. Targeted therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse effects than conventional non-targeted therapies. For example, in 20% of the cases, breast cancer is associated with the overexpression of HER2. In such circumstances, drugs such as Herceptin and Kadcyla, which target HER2 receptors, are administered as monotherapies or in combination. Targeting multiple pathways reduces the risk of developing treatment-resistant disorders. Thus, combination therapies, which target distinct mechanisms, are highly efficacious in treating cancer.”

According to the report, an increased in the demand for cancer monoclonal antibodies will have a big impact on the market. The development and rising demand for cancer monoclonal antibodies have been attributed to the recent understanding of the type of cancer at the molecular level. Monoclonal antibodies have a high affinity for specific disease cells and areas that need treatment. The use of cancer monoclonal antibodies is growing, including therapies such as radioimmunotherapy and antibody-directed enzyme prodrug therapy (ADEPT). The rising use of these antibodies in drug development increases the revenue generation in the global cancer monoclonal antibodies market, thereby contributing to market growth.

Further, the report states that the expiry of drug patents will lead to reduced sales of key drugs.

Companies Mentioned

Amgen Inc., Bristol-Myers Squibb, F. Hoffman-La Roche, GlaxoSmithKline Plc, Merck Inc., Takeda Pharmaceuticals, AbbVie, ADC Therapeutics, Agensys, Astellas, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, Boehringer-Ingelheim, Celgene, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed, Pfizer, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, TG Therapeutics, XBiotech.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Cancer immunotherapies in global cancer drugs market
  • Overview of cancer immunotherapies
    • Epidemiology
      • Table Global incidence of cancer by type 2015
      • Table Global mortality by cancer type 2015
      • Table Estimated numbers of male and female cancer survivors by age in US 2014
    • Spending on cancer
      • Table Spending on cancer by distribution channels 2013
    • Cost of cancer treatment
      • Table Annual treatment cost per patient for cancer immunotherapies 2014
      • Table Average cost of surgeries associated with cancer ($ millions) 2014
    • Reimbursement policies
      • Table National reimbursement of cancer drugs by countries 2014
    • Economic burden of cancer
    • Orphan drug designation and regulatory approvals
      • Table US FDA Orphan drug designations and approvals for cancer immunotherapies
      • Table EU orphan drug designations and approvals for cancer immunotherapies
      • Table Key events in cancer immunotherapies, discovery, and approvals
      • Table Timeline of some cancer immunotherapies
  • Pipeline portfolio
    • Table Phase III pipeline molecules for global cancer monoclonal antibodies market
    • Table Phase II pipeline molecules for global cancer monoclonal antibodies market
    • Table Phase I pipeline molecules for global cancer monoclonal antibodies market
    • Table Pipeline molecules for global immune checkpoint inhibitors market
    • Table Phase III pipeline molecules for global cancer vaccines market
    • Anticipated number of products with single and multi-indications by 2020
      • Table Near-launch immuno-oncology pipeline assets
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global cancer immunotherapies market 2015-2020 ($ billions)
      • Table Factors influencing global cancer immunotherapies market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type
    • Table Global cancer immunotherapies market by type 2015
    • Cancer monoclonal antibodies
      • Table Timeline for approvals of cancer monoclonal antibodies by US FDA
    • Clinical trials of cancer monoclonal antibodies
      • Table Clinical trials of cancer monoclonal antibodies by development phase
      • Table Status of clinical trials of cancer monoclonal antibodies
    • Immune checkpoint inhibitors
    • Cancer vaccines
    • Non-specific immunotherapies
      • Table Global cancer immunotherapies market by type of cancer immunotherapies 2015
      • Table Global cancer immunotherapies market by type of cancer immunotherapies 2015-2020 ($billions)
    • Global cancer monoclonal antibodies market
      • Table Global cancer monoclonal antibodies market 2015-2020 ($ billions)
      • Table Key drivers and challenges of global cancer monoclonal antibodies market
    • Global cancer vaccines market
      • Table Global cancer vaccines market 2015-2020 ($ billions)
      • Table Global cancer vaccines market by application 2015
      • Table Key drivers and challenges of global cancer vaccines market
    • Global immune checkpoint inhibitors market
      • Table Global immune checkpoint inhibitors market 2015-2020 ($ billions)
      • Table Key drivers and challenges for global immune checkpoint inhibitors market
    • Global non-specific immunotherapies market
      • Table Global non-specific immunotherapies market 2015-2020 ($ billions)
  • Geographical segmentation
    • Global cancer immunotherapies market by geography 2015-2020
      • Table Global cancer immunotherapies market by geography 2015
      • Table Global cancer immunotherapies market revenue by geography 2015-2020 ($ billions)
    • Cancer immunotherapies market in Americas
      • Table Cancer immunotherapies market in Americas 2015-2020 ($ billions)
    • Cancer immunotherapies market in EMEA
      • Table Cancer immunotherapies market in EMEA 2015-2020 ($ billions)
    • Cancer immunotherapies market in APAC
      • Table Cancer immunotherapies market in APAC 2015-2020 ($ billions)
  • Market drivers
    • Increase in prevalence of cancers
      • Table Global incidence of cancer 2015 and 2020 in millions
    • Increase in demand for cancer monoclonal antibodies
    • Patient assistance programs
    • Promising pipeline
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Patent expiry of top-selling drugs
      • Table Patent expiries of major cancer monoclonal antibodies by 2020
    • Poor diagnosis and screening
    • High developmental costs
    • Risk of side-effects
    • Stringent regulations
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Increase in cancer awareness
    • Emergence of targeted and combination therapies
      • Table Expected combination regimen launches in oncology
    • Emergence of biosimilars
    • Strategic alliances
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2015
      • Table Top cancer immunotherapies based on sales 2014 ($ billions)
      • Table YoY Sales comparison of top drugs 2011-2014 ($ billions)
      • Table Cancer immunotherapy companies by origin country
    • Amgen
      • Table Amgen: YoY growth and revenue generated from net product sales of Xgeva 2011- 2014 ($millions)
      • Table Amgen: YoY growth and revenue generated from net product sales of Prolia 2011- 2014 ($millions)
      • Table Amgen: YoY growth and revenue generated from net product sales of Vectibix worldwide excluding Japan 2011-2014 ($ millions)
      • Table Amgen: YoY growth and revenue of Vectibix in US 2012-2014 ($ millions)
      • Table Amgen: YoY growth and revenue of Vectibix in ROW 2012-2014 ($ millions)
      • Table Amgen: Key takeaways
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb: Segmentation by revenue 2014
      • Table Bristol-Myers Squibb: Revenue of oncology products by category 2014
      • Table Bristol-Myers Squibb: YoY growth and revenue generated from net product sales of Yervoy 2011-2014 ($ millions)
      • Table Bristol-Myers Squibb: YoY growth and revenue of Erbitux in US, Canada, and Japan 2010-2014($ millions)
      • Table Bristol-Myers Squibb: Key takeaways
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of MabThera/Rituxan 2011-2014 ($ billions)
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2011-2014 ($ billions)
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin2011-2014 ($ billions)
      • Table F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in US 2013-2014 ($ billions)
      • Table F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in EU 2013-2014 ($ billions)
      • Table F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in Japan 2013-2014 ($ millions)
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta2012-2014 ($ millions)
      • Table F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2014 ($millions)
      • Table F. Hoffmann-La Roche: Key takeaways
    • GlaxoSmithKline
      • Table GlaxoSmithKline: YOY growth and revenue of Arzerra 2012-2014 ($ millions)
      • Table GlaxoSmithKline: YOY growth and revenue of Cervarix 2012-2014 ($ millions)
      • Table GlaxoSmithKline: Key takeaways
    • Merck
      • Table Merck: YoY growth and revenue of Gardasil 2012-2014 ($ billions)
      • Table Merck: YoY growth and revenue generated from net product sales of Erbitux, excluding US,Canada, and Japan 2011-2014 ($ billions)
      • Table Merck: YOY growth and revenue of Erbitux in Europe 2012-2014 ($ millions)
      • Table Merck: YOY growth and revenue of Erbitux in emerging markets 2012-2014 ($millions)
      • Table Merck: YOY growth and revenue of Erbitux in ROW 2012-2014 ($ millions)
      • Table Merck: Region-wise revenues of Erbitux 2012-2014 ($ millions)
      • Table Merck: Key takeaways
    • Takeda Pharmaceuticals
      • Table Takeda Pharmaceuticals: YoY growth and revenue generated from net product sales ofAdcetris($ millions)
      • Table Takeda Pharmaceuticals: YoY growth and revenue of Vectibix in Japan ($ millions)
      • Table Takeda Pharmaceuticals: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report